Citations

Mayo Clinic

Showing 10 of 108602 citations.

Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling
Chen, Vicky Ping , Gao, Yang , Geng, Liyi, Brimijoin, Stephen

Proceedings of the National Academy of Sciences | October 2, 2017 | Volume: 114 | Issue: 41 | Pages: 10960-10965

10.1073/pnas.1706517114 | PMID 28973869 Get It

Significance Obesity is a major public health problem affecting physical and emotional well-being. Although lifestyle-based programs can help with weight loss, avoiding weight regain is nearly impossible because of persistent hormonal adaptations. Here, in mouse models, we explored a more effective strategy using viral gene transfer of butyrylcholinesterase (BChE) to control the appetite-mediating hormone acyl-ghrelin. We found that a single injection of BChE vector led to a lifetime high enzyme expression and lower circulating acyl-ghrelin. This same treatment suppressed postdieting hyperphagia, corrected metabolic lesions, and lowered weight regain. This outcome confirms the impact of the BChE-ghrelin axis on body weight and indicates that BChE gene transfer could be a successful strategy for long-term control of obesity and the “metabolic syndrome.”
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Campone, Mario , Sohn, Joohyuk , Paluch–Shimon, Shani , Huober, Jens , Park, In Hae , Trédan, Olivier , Chen, Shin‐Cheh , Manso, Luís , Freedman, Orit, Jaliffe, Georgina Garnica, Forrester, Tammy , Frenzel, Martin, Barriga, Susana , Bourayou, Nawel, Leo, Angelo Di , Toi, Masakazu , Paluch-Shimon, Shani, Freedman, Orit C, Garnica Jaliffe, Georgina, Smith, Ian C., Di Leo, Angelo, Hae Park, In , Di Leo, Angelo , Goetz, Matthew P. , Smith, Ian C., Manso Sanchez, Luis , Sohn, Joohyuk

Journal of Clinical Oncology | October 2, 2017 | Volume: 35 | Issue: 32 | Pages: 3638-3646

10.1200/jco.2017.75.6155 | PMID 28968163 Get It

Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm ( P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
BubR1 and brain aging
Hussaini, Syed Mohammed Qasim, Jang, Mi‐Hyeon , Hussaini, S. M. Qasim

Aging | October 2, 2017 | Volume: 9 | Issue: 9 | Pages: 1955-1956

10.18632/aging.101300 | PMID 29017149 Get It

Adipose tissue DNA methylome changes in development of new-onset diabetes after kidney transplantation
Baheti, Saurabh , Singh, Prachi , Zhang, Yun , Evans, Jared M., Jensen, Michael D. , Kocher, Jean‐Pierre , Sun, Zhifu , Chakkera, Harini A. , Evans, Jared, Sun, Zhifu , Somers, Virend K. , Singh, Prachi , Chakkera, Harini A

Epigenomics | October 2, 2017 | Volume: 9 | Issue: 11 | Pages: 1423-1435

10.2217/epi-2017-0050 | PMID 28967791 Get It

Lesser Trochanter Osteoplasty for Ischiofemoral Impingement
Goodwin, Jill A., Patel, Karan A. , Hartigan, David E. , Patel, Karan , Chhabra, Anikar

Arthroscopy Techniques | October 2, 2017 | Volume: 6 | Issue: 5 | Pages: No page available

10.1016/j.eats.2017.06.047 | PMID 29399462 Get It

Abstract Ischiofemoral impingement is a newly recognized cause of extra‐articular hip pain, and is caused by contact between the lesser trochanter and ischium. Surgical intervention has been proven successful for patients with persistent pain and disability after failure of nonoperative management. This technique article provides a reliable method for endoscopic lesser trochanter osteoplasty using an anterior approach. Technique Video video See video under supplementary data.
Tracheal decellularization using a combination of chemical, physical and bioreactor methods
Tchoukalova, Yourka D. , Hintze, Justin M. , Hayden, Richard E. , Tchoukalova, Yourka , Hintze, Justin , Lott, David G.

The International Journal of Artificial Organs | October 2, 2017 | Volume: 41 | Issue: 2 | Pages: 100-107

10.5301/ijao.5000648 | PMID 28967085 Get It

Introduction: The purpose of this study was to compare different decellularization protocols with the conventional detergent enzymatic method (DEM) using continuous agitation. Methods: The first experiment compared conventional DEM with sonication and lyophilization+freeze-thaw cycles. A second experiment was carried out to compare time-adjusted DEM (2-hour instead of 4-hour incubations with 4% deoxycholate) to decellularization in a bioreactor. Cellularity was determined by DNA-quantitation, H&E-staining and immunostaining for major histocompatibility complex-1 (MHC-1). Results: Compared to untreated trachea, DNA content significantly decreased after 2 cycles in all groups in the first experiment and dropped below the minimal criteria for efficient decellularization (<50 ng dsDNA/mg dry weight) after 4 cycles. However, nuclei were seen in the cartilage and MCH-1 staining was detected in some submucosal areas, indicating presence of chondrocytes and cellular residues that may render the scaffold immunogenic. In the second experiment DNA content significantly decreased after 1 cycle in both groups; however, even after 4 cycles, DNA content was above the minimal criteria for efficient decellularization. While collagen-levels remained stable, glycosaminoglycans diminished significantly after the initial cycles. Conclusions: Efficient decellularization can be achieved after only 4 cycles of DEM compared to the 17 cycles previously reported. The use of a bioreactor can preserve the integrity of the extracellular matrix.
Communicating Value in Simulation: Cost–Benefit Analysis and Return on Investment
Asche, Carl V. , Kim, Minchul , Brown, Alisha, Golden, Antoinette, Laack, Torrey A. , Rosario, Javier , Strother, Christopher , Totten, Vicken Y. , Okuda, Yasuharu

Academic Emergency Medicine | October 1, 2017 | Volume: 25 | Issue: 2 | Pages: 230-237

10.1111/acem.13327 | PMID 28965366 Get It

AbstractValue‐based health care requires a balancing of medical outcomes with economic value. Administrators need to understand both the clinical and the economic effects of potentially expensive simulation programs to rationalize the costs. Given the often‐disparate priorities of clinical educators relative to health care administrators, justifying the value of simulation requires the use of economic analyses few physicians have been trained to conduct. Clinical educators need to be able to present thorough economic analyses demonstrating returns on investment and cost‐effectiveness to effectively communicate with administrators.At the 2017 Academic Emergency Medicine Consensus Conference “Catalyzing System Change through Health Care Simulation: Systems, Competency, and Outcomes,” our breakout session critically evaluated the cost‐benefit and return on investment of simulation. In this paper we provide an overview of some of the economic tools that a clinician may use to present the value of simulation training to financial officers and other administrators in the economic terms they understand. We also define three themes as a call to action for research related to cost–benefit analysis in simulation as well as four specific research questions that will help guide educators and hospital leadership to make decisions on the value of simulation for their system or program.
Antiepileptic drug‐related neuropsychiatric adverse events in brain tumor‐related epilepsy: levetiracetam front and center
Feyissa, Anteneh M. , Feyissa, A M

European Journal of Neurology | September 30, 2017 | Volume: 24 | Issue: 12 | Pages: 1435-1436

10.1111/ene.13399 | PMID 28963765 Get It

Click here to view the accompanying paper in this volume.
Transcatheter aortic valve replacement for stenotic bicuspid aortic valves: Systematic review and meta analyses of observational studies
Reddy, Gautam , Greason, Kevin L. , Yoon, Sung‐Han , Makkar, Raj , Holmes, David R. , Wang, Zhen , Nishimura, Rick A.

Catheterization and Cardiovascular Interventions | September 30, 2017 | Volume: 91 | Issue: 5 | Pages: 975-983

10.1002/ccd.27340 | PMID 28963771 Get It

AbstractObjectiveThe aim of this study was to perform a systematic review and meta‐analyses of observational studies of transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve stenosis (BcAV).BackgroundTAVR for BcAV stenosis has been associated with an increased incidence of paravalvular leaks, valve malposition, pacemaker placement and all‐cause mortality. The conclusions drawn have been limited by small sample sizes. The use of TAVR for BcAV stenosis remains controversial.MethodsWe searched multiple databases from the inception of the databases through September 30, 2016 for studies of TAVR for BcAV stenosis. We included all observational studies with more than one patient and at least 1 month of outcomes.ResultsWe analyzed 13 observational studies with 758 patients. Meta analyses showed device success rate of 95% [95% confidence interval (CI) 90.2% to 98.5%] and an early safety event in 16.9% [95% CI 12.2% to 22%]. At 30 days, moderate to severe paravalvular leak was seen in 12.2% [95% CI 3.1% to 24.8%] and new pacemaker implantation in 17.9% [95% CI 14.2% to 22%]. All‐cause mortality was 3.7% [95% CI 2.1% to 5.6%], which should be viewed in the context of an STS PROM of 5.0%.ConclusionsThis analysis suggests that TAVR for BcAV is not associated with excess mortality. The incidence of paravalvular leaks and pacemaker implant is increased compared to tricuspid aortic valve cohorts undergoing TAVR, and operators should weigh these potential complications against the clinical benefit provided by TAVR for BcAV patients at high risk for surgical valve replacement.
Does mild paravalvular regurgitation post transcatheter aortic valve implantation affect survival? A meta‐analysis
Ando, Tomo , Briasoulis, Αlexandros , Telila, Tesfaye , Afonso, Luis , Takagi, Hisato , Briasoulis, Alexandros, Takagi, Hisato , Briasoulis, Alexandros , Grines, Cindy L.

Catheterization and Cardiovascular Interventions | September 30, 2017 | Volume: 91 | Issue: 1 | Pages: 135-147

10.1002/ccd.27336 | PMID 28963761 Get It

AbstractBackgroundTo assess the impact of post transcatheter aortic valve implantation (TAVI) mild paravalvular regurgitation (PVR) on mortality. More than moderate PVR after TAVI has decreased with the advent of new‐generation prosthetic valves. However, mild PVR remains common and its clinical impact has been inconsistent. We aimed to assess the impact of mild PVR through meta‐analysis.Methods and ResultsA systematic literature search was conducted through PUBMED and EMBSE. Manuscripts that reported hazard ratio (HR) with 95% confidence interval (CI) for clinical outcome of interest (all‐cause and cardiac mortality) has been included. Random‐effects model was used for calculation of HR. A total of 25 articles including total of 21,018 patients were finally included for quantitative synthesis (meta‐analysis). Our pooled analysis demonstrated higher all‐cause mortality in patients with mild PVR compared to none/trivial PVR (HR 1.26, 95%CI 1.11–1.43, I2=45%, p < 0.001) (follow up duration range 6 months to 5 years). Significant heterogeneity among studies was observed (p for heterogeneity = 0.005). Egger's test showed no evidence of publication bias. Cardiovascular mortality was increased in patients with mild PVR compared with none/trivial PVR (HR 1.28, 95%CI 1.05–1.57, I2=8%, p = 0.02) (follow up duration range 1–3 years).ConclusionsMild PVR was associated with increased all‐cause and cardiovascular mortality after TAVI. Whether further interventions in mild PVR is of benefit, has yet to be determined.